Scholars Central

OtherPublished 22 Jul 2016

Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus

Authors: Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera

Clinical Investigation

Volume 5 · Issue 6 · Pages 561–571

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Treatment of patients with systemic lupus erythematosus (SLE) is still a challenge for many physicians and often associated with a range of adverse side effects. Based on the evidence of the central role of B cells in SLE pathogenesis, several new drugs have been developed. Inhibition of BAFF/APRIL system has appeared as one of the key factors in modulating B-cell response in patients with SLE. In 2011, belimumab was approved by the European and American regulatory agencies for the treatment of SLE patients. Four years later, consistent clinical experience has been accumulated. This article aims to review the mechanisms behind this system and the evidence provided by up-to-date trials on the safety, efficacy and effectiveness of belimumab in SLE patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Ignasi Rodriguez-Pinto”
  • BylineArticles whose byline prints “Gerard Espinosa1 & Ricard Cervera”